Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates

AIDS

Volumn 30, Issue 7, 2016, Pages 1015-1025

  Herrera, Carolina ^a,b   Armanasco, Naomi ^a,b   García Pérez, Javier ^c   Ziprin, Paul ^b   Olejniczak, Natalia ^b   Alcamí, José ^c   Nuttall, Jeremy ^d   Shattock, Robin J ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

antiretrovirals; combination; explant; mucosal; prevention

Indexed keywords

DAPIVIRINE; MARAVIROC; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PLACEBO; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLS; CLADISTICS; COLON; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; EX VIVO STUDY; EXPLANT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IC50; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RECTUM; VIRUS TRANSMISSION; BIOLOGICAL MODEL; CELL CULTURE; CHEMOPROPHYLAXIS; COMBINATION DRUG THERAPY; DISEASE TRANSMISSION; FEMALE; HIV INFECTIONS; MALE; ORGAN CULTURE TECHNIQUE; PRECLINICAL STUDY; PREVENTION AND CONTROL; PROCEDURES;

ANTI-HIV AGENTS; CELLS, CULTURED; CHEMOPREVENTION; CYCLOHEXANES; DISEASE TRANSMISSION, INFECTIOUS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; ORGAN CULTURE TECHNIQUES; PRE-EXPOSURE PROPHYLAXIS; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES;

EID: 84957675230     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001043     Document Type: Article

References (50)

1. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002; 324:757.
2. Pennings PS. HIV drug resistance: problems and perspectives. Infect Dis Rep 2013; 5:e5.
3. Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, et al. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retro-viruses 2014; 30:753-768.
4. Kalichman SC, Rompa D, Luke W, Austin J. HIV transmission risk behaviours among HIV-positive persons in serodiscordant relationships. Int J STD AIDS 2002; 13:677-682.
5. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectiv-ity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96.
6. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997; 146:350-357.
7. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
8. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, Hultin LE, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. Aids 2000; 14:1761-1765.
9. Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, Viora M, et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 1999; 29:1202-1208.
10. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(R) CXCR4(R) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001; 75:8390-8399.
11. Cranston RD, Hoesley C, Carballo-Dieguez A, Hendrix CW, Husnik M, Levy L, et al. A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010). AIDS Res Hum Retroviruses 2014; 30:184-189.
12. McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 2013; 8:e60147.
13. Anton P, Cranston R, Carballo-Dieguez A, Kashuba A, Khanu-khova E, Elliott J, et al. RMP-02/MTN-006: a phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. AIDS Res Hum Retroviruses 2012; 28:1412-1421.
14. Ventuneac A, Carballo-Dieguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 2010; 14:618-628.
15. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, et al. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 2011; 6:e23243.
16. McGowan I. The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv 2014; 11:69-82.
17. Grivel JC, Shattock RJ, Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med 2011; 9 (Suppl 1):S6.
18. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289.
19. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
20. Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, et al. Nonaqueous silicone elastomer gels as a vaginal micro-bicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011; 156:161-169.
21. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2013; 68:678-683.
22. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202:739-744.
23. Chen BA, Panther L, Hoesley C, Hendrix C, van der Straten A, Husnik M, et al. Safety and pharmacokinetics/pharmacody-namics of dapivirine and maraviroc vaginal rings. J Acquir Immune Defic Syndr 2015; 70:242-249.
24. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233:215-219.
25. Li Y, Hui H, Burgess CJ, Price RW, Sharp PM, Hahn BH, Shaw GM. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol 1992; 66:6587-6600.
26. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 1991; 65:3973-3985.
27. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 2013; 110:6626-6633.
28. Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, et al. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology 2015; 12:50.
29. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
30. Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, et al. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology 2013; 442:51-58.
31. Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retro-virology 2013; 10:43.
32. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-8367.
33. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864.
34. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
35. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4R T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995; 69:3712-3720.
36. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999; 73:684-694.
37. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009; 53:1797-1807.
38. Herrera C, Klasse PJ, Michael E, Kake S, Barnes K, Kibler CW, et al. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005; 338:154-172.
39. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. Aids 2006; 20:1237-1245.
40. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, et al. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 2013; 87:2401-2411.
41. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, et al. Comparison of viral Env proteins from acute and chronic infections of subtype C human immunodeficiency virus type 1 identifies differences in glycosy-lation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 2013; 87:7218-7233.
42. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127-139.
43. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2:a007385.
44. McGowan I, Dezzutti C. Rectal microbicide development. Curr Top Microbiol Immunol 2014; 383:117-136.
45. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. Aids 2011; 25:1971-1979.
46. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc(UK-427;857), apotent, orallybioavailable, andselec-tive small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
47. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, et al. Recent advancesin the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008; 375:315-320.
48. Chou T-C, Talalay P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-menten kinetic systems. J Biol Chem 1977; 252:6438-6442.
49. Chou J, Chou T-C. Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist 1988; 30:231.
50. Menéndez-Arias L. Molecular basis of human imunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 2013; 98:93-120.